The CKMT2 antibody targets the creatine kinase mitochondrial 2 (CKMT2) protein, a key enzyme in cellular energy metabolism. CKMT2. also known as ubiquitous mitochondrial creatine kinase, is primarily located in the mitochondrial intermembrane space and plays a critical role in the phosphocreatine shuttle system. This system facilitates ATP regeneration by transferring high-energy phosphates from mitochondria to cytosolic sites, ensuring energy homeostasis in cells with high metabolic demands, such as cardiac and skeletal muscle, brain, and sperm cells. CKMT2 forms dimers or octamers, with its activity regulated by calcium, magnesium, and adenosine nucleotides.
Antibodies against CKMT2 are widely used in research to study mitochondrial function, energy metabolism disorders, and diseases linked to bioenergetic deficits, including neurodegenerative conditions, cardiomyopathies, and cancer. CKMT2 dysregulation has been implicated in tumor progression, as altered creatine kinase activity may promote cancer cell survival under hypoxic conditions. In immunostaining or Western blot applications, CKMT2 antibodies help assess protein expression levels, subcellular localization, and post-translational modifications. Specificity validation via knockout controls or siRNA knockdown is essential due to structural similarities with other creatine kinase isoforms. These tools advance understanding of CKMT2's role in health and disease, bridging metabolic pathways and cellular stress responses.